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Background: Chronic diseases, such as cardiovascular disease and type 2 diabetes, impose significant burden to
public health. Most chronic diseases are associated with underlying preventable risk factors, such as elevated blood
pressure, blood glucose, and lipids, physical inactivity, excessive sedentary behaviours, overweight and obesity, and
tobacco usage. Sugar-sweetened beverages are known to be significant sources of additional caloric intake, and
given recent attention to their contribution in the development of chronic diseases, a systematic review is
warranted. We will assess whether the consumption of sugar-sweetened beverages in adults is associated with
adverse health outcomes and what the potential moderating factors are.
Methods/Design: Of interest are studies addressing sugar-sweetened beverage consumption, taking a broad
perspective. Both direct consumption studies as well as those evaluating interventions that influence consumption
(e.g. school policy, educational) will be relevant. Non-specific or multi-faceted behavioural, educational, or policy
interventions may also be included subject to the level of evidence that exists for the other interventions/exposures.
Comparisons of interest and endpoints of interest are pre-specified. We will include randomized controlled trials,
controlled clinical trials, interrupted time series studies, controlled before-after studies, prospective and retrospective
comparative cohort studies, case-control studies, and nested case-control designs. The MEDLINE®, Embase, The
Cochrane Library, CINAHL, ERIC, and PsycINFO® databases and grey literature sources will be searched. The
processes for selecting studies, abstracting data, and resolving conflicts are described. We will assess risk of bias
using design-specific tools. To determine sets of confounding variables that should be adjusted for, we have
developed causal directed acyclic graphs and will use those to inform our risk of bias assessments. Meta-analysis
will be conducted where appropriate; parameters for exploring statistical heterogeneity and effect modifiers are
pre-specified. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will
be used for determining the quality of evidence for outcomes.
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Chronic diseases, such as cardiovascular disease and
type 2 diabetes, cause significant morbidity and mortality
worldwide. To address the burden of chronic diseases
on the health of populations, effective interventions and
public health policies are required. Most chronic disea-
ses are associated with underlying preventable risk fac-
tors, such as elevated blood pressure, high blood glucose
or glucose intolerance, hyperlipidemia, physical inactivity,
excessive sedentary behaviours, overweight and obesity,
and tobacco usage. The development of chronic diseases
may be prevented if these risk factors are addressed before
they progress to overt disease. A simple, unidirectional
schematic depicts the hypothesized pathways by which
sugar-sweetened beverage (SSB) consumption may lead to
the development of chronic cardiovascular/cerebrovascu-
lar and metabolic diseases, chronic kidney disease, cancer,
and gout (Additional file 1). These mechanisms have not
been conclusively established by research studies, and se-
veral conflicting theories have been put forward [1-8].
However, as some of the SSB constituents, notably sugar
but also caffeine and by-products of caramel colouring,
where added, are postulated to be involved in the mecha-
nisms of disease development, they are included in our
depiction of the disease pathways.
Recent attention has focused on the contribution of
SSBs to the chronic disease epidemic. In an attempt to
curb rising rates of obesity, New York City has proposed
a ban on the sale of large-sized SSB products greater
than 16 oz, including sodas, sweetened teas and coffees,
energy drinks, and fruit drinks in restaurants, delis,
sports arenas, movie theatres, and food carts [9]. The
proposed ban has been twice rejected but is being re-
viewed by the United States (US) Court of Appeals. In
March 2014, the World Health Organization (WHO)
released draft guidelines with recommendations on lim-
iting sugar consumption (through food and beverage) to
reduce public health problems like obesity and dental
caries. They are recommending decreasing the total en-
ergy intake of sugar by day from 10% (recommended
since 2002) to 5% [10].
Some researchers hypothesize that SSBs are significant
sources of caloric intake. With the adjusted prevalence
of SSB consumption at 73% for young adults (20–34
years) and 50% among adults (35 years or older) accord-
ing to the 2007–2008 US National Health and Nutrition
Examination Survey (NHANES) data, the mean adjusted
SSB energy intake was 338 and 236 kcal/day, respectively
[11]. Heavy consumption (≥500 kcal/day) occurred among
20% of young adult and 12% of adult consumers [11].
Soda was the most heavily consumed SSB [11].
Several reviews have presented evidence syntheses on
associations between SSB consumption and metabolic
syndrome/type 2 diabetes, [12-14] weight, [12,14-17], andcardiovascular disease [12]. In a meta-analysis of 11
prospective cohort studies, the highest quantile of SSB
consumption (one to two servings/day) was associated
with a statistically significant increased risk of deve-
loping type 2 diabetes (risk ratio (RR) = 1.26, 95% confi-
dence interval (CI): 1.12–1.41) and metabolic syndrome
(RR = 1.20, 95% CI: 1.02–1.42) in adults [13]. Vartanian
et al. found associations between SSB consumption and
increased energy intake and body weight, lower intake
of calcium and other nutrients, and increased risk of
medical problems such as type 2 diabetes, hypocalce-
mia, dental caries, and elevated blood pressure [15]. A
World Health Organization report concluded that the
evidence to implicate high intake of sugar-sweetened
drinks on weight gain is moderately strong [18]. In ad-
dition, in a systematic review conducted as part of the
Dietary Guidelines Advisory Committee deliberations,
the following conclusion statements were provided [19]:
 ‘Limited evidence shows that intake of sugar-
sweetened beverages is linked to higher energy
intake in adults’.
 ‘A moderate body of epidemiologic evidence suggests
that greater consumption of sugar-sweetened
beverages is associated with increased body weight
in adults’.
 ‘A moderate body of evidence suggests that under
isocaloric controlled conditions, added sugars,
including sugar-sweetened beverages, are no more
likely to cause weight gain than any other source of
energy’.
Other reviews, however, have concluded that the as-
sociation between SSB consumption and weight is close
to zero [16,20]. Some reviews report a dose-response rela-
tionship between SSB and weight status but no corres-
ponding weight loss when SSB consumption was reduced
[21]. A systematic review of epidemiological research
analysed beverages by category (water, milk, soft drinks,
sugary drinks, non-carbonated, fruit juices, carbonated
beverages, hot beverages, and alcoholic beverages), and
the authors concluded that the results were inconsistent
and did not establish an association between beverage
intake and subsequent weight gain [22]. Within their
beverage categories, however, the authors did not con-
sistently separate SSBs from other drinks; for example,
sweetened hot beverages were not differentiated from
non-sweetened. Others have reviewed the biological
plausibility of SSBs to uniquely affect the physiologi-
cal energy balance regulatory systems (e.g. satiety and
post-prandial regulatory systems) and concluded that
known biological mechanisms did not support the con-
cept that SSBs were somehow different from other sources
of energy [23].
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caloric intake. Although total caloric intake and caloric
intake from other dietary sources are factors that may be
thought of as confounders, some evidence suggests that
they may be clustered with SSB consumption and gen-
eral unhealthy eating habits [12,17,24]. Conflicting evi-
dence exists as to whether SSB intake is associated with
increased energy intake [15,19] and may lower the intake
of milk, calcium, and other nutrients [15]. Furthermore,
given that SSB consumption may alter taste preferences
and quality of diet, caloric intake may in fact mediate
the effect of SSB consumption and health outcomes (i.e.
it may lie in the causal pathway).
The available systematic review evidence is not only
conflicting but fraught with several methodological is-
sues, and it is difficult, therefore, to make any firm
conclusions about the health effects of SSBs [25]. The
definition of what constitutes an SSB, for example, may
vary and may not be explicitly described [15-17,26,27].
Reviews may not have accounted for all variables that
can confound associations between SSB consumption
and health outcomes. Most reviews have addressed sin-
gular outcomes of interest to public health. Further, new
primary evidence [28-30] on the topic is rapidly accumu-
lating since the last systematic review was published in
2011. We will attempt to overcome some of the meth-
odological challenges encountered in other reviews by
carrying out a rigorous assessment of the internal valid-
ity of individual studies, which will include an evaluation
of confounding and biasing factors using causal directed
acyclic graphs (DAGs) [31].
Objectives
The objective of the systematic review is to answer the
following research questions:
In adults, does the consumption of SSBs cause adverse
health outcomes? If so, what potential moderating
factors affect the causal association between SSB
consumption and outcomes?
Methods/Design
Eligibility criteria
Studies will be selected according to the criteria outlined
below.
Study designs
We will include randomized controlled trials (RCTs), in-
cluding cluster RCTs, controlled (non-randomized) clin-
ical trials (CCTs) or cluster trials, interrupted time series
(ITS) studies with at least three data points before and
after the intervention [32], controlled before-after (CBA)
studies, prospective and retrospective comparative cohort
studies, and case-control or nested case-control studies.Cluster randomized, cluster non-randomized, or CBA stu-
dies will be included only if there are at least two inter-
vention sites and two control sites [32]. We will exclude
cross-sectional studies, case series, and case reports.
Participants
We will include studies examining the general adult hu-
man population or healthy adult humans (18 years or
older). We will also include studies on people who are
overweight or obese, but will otherwise exclude studies
of populations restricted to specific diseases, conditions,
or metabolic disorders. We will include studies address-
ing both adults and children if data provided for adults
are reported separately.
Interventions
Of interest are interventions addressing SSB consump-
tion, taking a broad perspective. In addition to direct
consumption studies, we would consider interventions
that influence consumption, such as those addressing
the level of access to SSBs (e.g. university/college policy)
and educational interventions addressing consumption
as relevant. Non-specific or multi-faceted behavioural,
educational, or policy interventions may also be included
subject to the level of evidence that exists for the afore-
mentioned interventions/exposures. We will also consider
other types of interventions on a case-by-case basis, sub-
ject to what exists in the literature.
In terms of defining an SSB, we view them as akin to a
complex intervention because they are composed of sev-
eral parts. For example, in addition to sugar, some be-
verages contain caffeine and the by-products of caramel
colouring (2-methylimidazole, 4-methylimidazole), which
may contribute independently to adverse health outcomes.
The scope of the review, therefore, warrants an examin-
ation of SSB consumption as a whole, rather than the spe-
cific constituents as exposure variables. Otherwise, such
evaluations would have necessarily required the inclusion
of studies addressing those constituents and in foods and
drinks other than SSBs.
We will use the Centers for Disease Control and Pre-
vention (CDC) definition of SSB for drinks that should
be included. According to the CDC, SSBs contain added
caloric sweeteners [33], which would include natural
sweeteners such as honey and concentrated fruit juice.
We have developed a classification scheme based on the
CDC definition for use during the review (see classifi-
cation scheme for SSBs below). For beverages such as
coffee, tea, and homemade lemonade, studies will be in-
cluded in the review if they explicitly state that sugar
was added. We will exclude artificially sweetened (e.g.
with aspartame or sucralose) beverages, alcoholic be-
verages, and 100% fruit or vegetable juices as exposures/
interventions.
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the following broad categories:
 Sodas—caffeinated/non-caffeinated (soft drinks,
soda, pop, soda pop)
 Other non-carbonated sweetened beverages
(fruitades, fruit drinks, fruit punches, [iced] teas,
coffees, non-dairy fruit smoothies)—caffeinated/
non-caffeinated
 Fortified sweetened beverages (energy drinks,
fortified waters, sports drinks)—caffeinated/
non-caffeinated and containing vitamins, amino
acids, herbal stimulants, or other ingredients
 Flavored/sweetened milk or milk alternative
beverages (dairy, soy, almond, milkshakes,
dairy-based fruit smoothies)—caffeinated/
non-caffeinated
Comparators
Given the broad perspective for interventions of interest,
several comparisons will be relevant to include. Some
may be more likely to come from observational designs
and others from experimental studies.
Direct consumption studies:
1. SSB consumption compared with consumption of
non-SSB drink (e.g. 100% fruit juice, artificially
sweetened beverage, water)
2. Higher level of SSB consumption versus lower level
of SSB consumption for the same drink type (e.g.
carbonated cola beverages)
3. Comparisons among different categories of SSBs
(e.g. soft drinks compared with fruit drinks; see
classification scheme for SSBs) consumed in similar
amounts
Interventions that influence consumption:
4. One level of access to SSB compared with another
level of access (e.g. university/college policy on
beverages in vending machines)
5. Educational intervention to specifically promote
lower or no SSB consumption compared
with no educational intervention/regular
curriculum coverage/general health-focussed
intervention
6. Non-specific or multi-faceted educational,
behavioural, or policy dietary intervention (may
include component of SSB consumption)
compared with no intervention
7. Other comparisons involving interventions that
address our research question (interventions
assessed on a case-by-case basis, as encountered in
the literature)For comparator groups 2 and 3, we anticipate that vol-
ume will be the most feasible to analyse; however, we
will extract all measures in which consumption is re-
ported (e.g. volume, caloric intake from sugar) in studies
to see what analysis is possible.
For feasibility, category 6 comparisons (non-specific,
multi-faceted interventions) will be coded at title/abstract
screening and not put through to full-text screening. If
sparse evidence exists in the other potential comparison
types, we will revisit eligibility for comparison 6.
Outcomes
Endpoints important for decision-making are of primary
interest. If reported on, these will be analysed and graded.
If a given clinical endpoint is not reported on, we will
analyse and grade their relevant surrogate outcome(s).
 Endpoints important for decision-making:
– Adverse cardiovascular (including
cerebrovascular) events
– Cancer (excluding basal cell and squamous cell
carcinoma)
– Chronic kidney disease
– Mortality
– Overweight/obesity
– Type 2 diabetes
– Dental caries
– Quality of life (generic, validated tools only, such
as those in Additional file 2)
– Gout Surrogate outcomes:
– Pre-diabetes
– Metabolic syndrome
– Change in cardiovascular disease (CVD) risk
– Progression of obesity
– Dyslipidemia
– HypertensionAs some outcomes may be reported as a composite
measure, we will extract all composite and individual out-
comes as reported in the studies.
Outcomes will be collected as reported, with the excep-
tion of quality of life, which will be collected only if assessed
with generic (not disease-specific), validated tools. Due to
possible variation in disease definitions over time, we will
extract definitions of outcomes as reported in individual
studies. We will extract outcomes in all data forms (e.g. di-
chotomous, continuous) as reported in the included studies.
Timing
Studies will be selected for inclusion based on the length
of follow-up of outcomes. The following will be used as
a guide for all study designs:
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studies should have a follow-up time of at least
1 year.
 For all surrogate outcomes, studies should be at
least 6 months duration for follow-up.
 For cancer, studies should be at least 1 year duration
for follow-up. Some types of cancer may need longer
than a 1-year follow-up, but this will be evaluated
on a case-by-case basis.
Setting
There will be no restrictions by type of setting.
Language
We will include articles reported in the English and
French languages. A list of possibly relevant titles in
other languages will be provided as an appendix.
Search methods
Electronic searches
A comprehensive literature search using high-recall sub-
ject searches will be conducted in MEDLINE®, Embase,
CINAHL, PsycINFO®, ERIC, and The Cochrane Library.
Electronic search strategies (Additional file 3), guided by
an experienced information specialist, have been devel-
oped and peer-reviewed according to the peer review of
electronic search strategies (PRESS) guidelines [34]. The
search will not be restricted for time period or the lan-
guage of publication. We will exclude comments, letters,
and editorials.
Other sources
Grey literature sources, such as websites listed within
the Canadian Agency for Drugs and Technologies in
Health’s (CADTH) Grey Matters checklist, the Federation
of American Societies for Experimental Biology (FASEB)
meeting abstracts, the Obesity Society abstracts, the Food
and Nutrition Conference and Expo (FNCE) abstracts, the
International Diabetes Federation website, the Centers for
Disease Control and Prevention website, the Rudd Center
for Food Policy and Obesity website, the Obesity and
Energetics Offerings website, the American Heart Asso-
ciation, the European Union, the Center for Science in the
Public Interest, the 20th International Congress of Nutri-
tion, the American Beverage Association, and Refresh-
ments Canada will be searched. We will consult within
the research team for relevant studies that may not be in
the published literature. We will scan the references of in-
cluded studies and relevant reviews for additional articles
and perform a forward search on key articles. We will
search ClinialTrials.gov, the WHO International Clinical
Trials Registry Platform, and the International Association
for the Study of Obesity (IASO) for completed and on-
going studies.Study selection process
Literature search results will be de-duplicated in Reference
Manager [35] before uploading to Distiller Systematic
Review Software® (Distiller SR), an online program that
facilitates screening and data extraction [36]. Screening
questions will be developed and pilot-tested with a subset
of records before implementation. All titles and abstracts
of records will be screened by one person; those deemed
not relevant will be verified by a second person for exclu-
sion. Full-text reports for all potentially relevant records
and those without an available abstract will be screened by
two independent reviewers. Discrepancies will be resolved
by consensus or a third person. The study selection pro-
cess will be reported using the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram [37], including reasons for excluding full-
text articles.
Data collection and analysis
Data extraction and management
Feedback will be solicited from the research team on the
draft list of data variables for extraction. Data extraction
forms will be developed and pilot-tested in Distiller SR.
One person will extract all information. A second person
will verify 20% of studies for general characteristics in-
formation and 100% of studies regarding outcomes data.
Disagreements will be resolved by consensus or by a third
team member, if needed. Information on the descriptive
and quantitative characteristics of studies will include the
following:
 Publication details (e.g. year of publication, language,
publication status)
 Characteristics of study (e.g. study design, methods,
country, setting, sample size, number of centres [if
applicable], duration of follow-up, source of funding)
 Characteristics of population (e.g. age, gender,
ethnicity, co-interventions, information regarding
respondent bias/representativeness of the included
population)
 Details about the exposure/intervention (e.g. type
and category of SSB [see classification scheme for
SSBs]), brand name, amount of sugar/serving, type
of added sugar, amount of caffeine, other specific
ingredients and their quantification, frequency of
use, amount consumed in millilitres, SSB caloric
content, percent of total calories obtained from
SSB consumption, method of assessing SSB
consumption; type of educational or other
interventions and description, type of professional
delivering intervention)
 Details about comparator group (e.g. for beverages:
identity, frequency of use, amount used, brand
name, specific ingredients)
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follow-up (definitions, measurement methods, data,
adjusted and unadjusted effect estimates)
 Confounding factors that were taken into
consideration
 Risk of bias items
Assessing the risk of bias
The risk of bias for each included study will be assessed
by one member of the research team and verified by a
second member. Disagreements will be resolved by con-
sensus or by a third team member, if needed. Assessment
tool questions were reorganized (as needed) to ensure that
domains relating to selection, confounding (where applic-
able), performance, attrition, detection, reporting, and
‘other’ biases were addressed in all tools. A modified ver-
sion of the Cochrane Risk of Bias tool will be used to
evaluate RCTs (Additional file 4) [38]. In addition to the
standard domains of bias, we will assess cluster trials for
the possibility of recruitment bias [39]. A modified version
of the Academy of Nutrition and Dietetics’ Evidence Ana-
lysis Library (EAL) Quality Criteria Checklist will be used
to evaluate observational studies and CCTs (Additional
file 4) [40]. We removed questions pertaining solely to
reporting characteristics, and we added a few other rele-
vant questions. To evaluate ITS and CBA studies, a modi-
fied Cochrane Effective Practice and Organisation of Care
(EPOC) tool will be used (Additional file 4) [41]. Study
sponsorship will be assessed for all studies. Each domain
within a tool will be judged as unclear, low, or high risk of
bias, with supporting information provided from the re-
port or reviewer interpretation to rationalize the judge-
ment of bias [38]. Some domains are outcome-specific
and will be assessed at the outcome level. The risk of
bias for outcomes will be factored into grading the quality
of evidence. The overall risk of bias for the body of evi-
dence will involve a judgement of the relative importance
of domains, guided by known empirical evidence of bias,
the likely direction of bias, and the likely magnitude of
bias [38]. We will follow the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
guidance for determining the extent of the risk of bias for
the body of evidence [42].
Step 1—Assessment of risk of bias for individual stu-
dies for a given outcome
 Low risk of bias: when all key domains are at a low
risk of bias
 Moderate risk of bias: crucial limitation for one
domain or some limitations for multiple domains
sufficient to lower confidence in the effect estimate
 High risk of bias: crucial limitation for one or more
domains sufficient to substantially lower confidence
in the effect estimateStep 2—Assessment of risk of bias for the body of evi-
dence across studies for a given outcome (incorporated
into GRADE assessments as one of the required domains)
 No serious limitation, do not downgrade: body of
evidence mostly from studies at a low risk of bias
 Serious limitations, downgrade one level: body of
evidence mostly from studies at moderate risk of
bias
 Very serious limitations, downgrade two levels: body
of evidence mostly from studies at high risk of bias
Regarding confounding bias, causal DAGs will be used
[31]. Causal DAGs are graphical models used in epide-
miology to determine sets of confounders that should be
adjusted for to obtain unbiased effect estimates. They
also identify biasing paths associated with selection bias.
By adjusting for only those confounders that are derived
from a causal DAG, the potential for over-adjustment or
the creation of selection bias by conditioning on colliders
(i.e. variables that are common effects of both the expos-
ure and outcome) are reduced, given that the causal DAG
is correct [43,44]. We will use the minimal sufficient ad-
justment sets generated from the causal DAGs as a guide
to determine if studies have adequately accounted for
confounding variables or created selection bias by over-
adjustment of imbalances between exposure and control
groups. For a given outcome, if studies differentially ac-
count for variables from the minimum adjustment sets,
we may not pool those studies in a meta-analysis. Draft
causal DAGs (Additional file 5) have been developed using
the DAGitty program [45]. The causal DAGs may be
modified to include important and justifiable variables we
encounter when reviewing included studies.
Dealing with missing data
If information or data are missing or incomplete, we will
attempt to contact the study authors twice over 2 weeks
by email. If feasible, we will incorporate loss-to-follow-
up data. We will not impute effect estimates, but will
impute missing standard deviations or standard errors
using data from other similar studies in the review, using
an approach suggested in the literature [46].
Data analyses
For dichotomous outcomes, the risk ratio or odds ratio
and 95% confidence intervals will be used for pooling.
For continuous outcomes, mean differences and 95% con-
fidence intervals will be used for pooling for outcomes re-
ported on the same scales or measured in the same units.
Standardized mean differences will be used for pooling
where continuous outcomes are reported using differ-
ent scales or measures. Transformation of data to allow
analyses with mean differences will be made, wherever
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extracted whether reported as post-intervention or change
from baseline. We will consider using the r value, a cor-
relation coefficient, for continuous variables when some
studies analyse as a dichotomous outcome and others ana-
lyse as a continuous outcome. Statistics from individual
studies will be converted to an r value before meta-
analysing [47,48]. The r value can be roughly interpreted
as a small (r = 0.1), medium (r = 0.3), or large (r = 0.5) ef-
fect size. We plan to transform the pooled r to another
statistic, such as an odds ratio, to aid in interpretation
[47]. For time-to-event data, the hazard ratio, which
is usually estimated from a Cox proportional hazards
model, will be pooled using the generic inverse variance
method [49]. Comprehensive Meta-Analysis will be used
for meta-analyses [50]. SAS software will be used for
meta-regression analyses [51].
Other statistical considerations
Sparse binary data and studies with zero events When
studies report rare events, narrative synthesis will suffice.
When event rates are less than 1%, the Peto odds ratio
method will be used. However, when control groups are
of unequal sizes, when large magnitude of effect is ob-
served, or when events become more frequent (5%–
10%), the Mantel-Haenszel method without correction
factor will be employed for quantitative synthesis [49].
Data conversions Where needed, we will convert data
(e.g. standard error to standard deviation) for use in ana-
lyses and to facilitate consistent presentation of results
across studies.
Interrupted time series designs If interrupted time se-
ries studies are included, we will re-analyse data, where
needed and if feasible, for change in level and slope ac-
cording to time series regression analyses [52].
Evidence synthesis
Study characteristics will be summarized narratively in
the text and shown in summary tables in the report.
Before meta-analyses are performed, studies will be as-
sessed for heterogeneity on clinical and methodological
characteristics; we plan to review these decisions with
the research team before conducting analyses. For out-
comes that can be measured on various scales (e.g. qual-
ity of life), heterogeneity of outcome measurements will
also be assessed before pooling. With sufficient homo-
geneity and quantity of data, we will pool studies using
standard random effects meta-analytic methods [53,54].
Any meta-analyses will be done separately for observa-
tional studies and experimental ones. Narrative synthesis
of data will be conducted when quantitative pooling
is considered inappropriate (team decision based on theaforementioned issues, such as disparate clinical charac-
teristics of included patients/participants). When impor-
tant clinical or methodological heterogeneity precludes
pooling, we may still present forest plots without a pooled
summary estimate to show individual study effects. Effect
estimates from observational studies at a high risk of bias
may be excluded from the evidence synthesis when their
findings are inconsistent with studies at a lower risk
of bias. If only observational studies at a high risk of
bias exist for a given outcome, we will not synthesize
those studies because they are unlikely to inform about
causality.
Statistical heterogeneity and effect modifiers
Statistical heterogeneity will be assessed using Cochrane
Q (considered statistically significant at p < 0.10) and
I-squared statistics. For the interpretation of I-squared, a
rough guide of low (0%–25%), moderate (25%–50%), sub-
stantial (50%–75%), and considerable (75%–100%) hetero-
geneity will be used [55,56]. When a body of evidence is
determined to be statistically heterogeneous, we plan to
explore the impact of moderating factors using a combin-
ation of subgroup analysis and meta-regression tech-
niques, where the optimal approach for each variable will
be determined once we see how data are reported in stu-
dies. Some variables (*) will be investigated as potential
effect modifiers regardless of heterogeneity tests. The dis-
tribution of several aspects of patient demographics, ex-
posure, and other characteristics will be of interest and
include the following:
 Participant age*
 Participants who are post-menopausal women
 Sex*
 Ethnicity*
 Region (to account for culture and life style)
 Overweight/obesity*
 CVD risk group*
 SSB category*
 Amount of SSB consumption*
 Type of comparator*
 Caffeine-containing drinks*
 Outcome definition
 Study design
 Duration of study
 Single versus multi-centre studies
 Risk of bias assessments
 Covariate adjustment
 Funding
 Adjustment for total caloric intake*
We will follow previously published guidance for meta-
regression [49]. Meta-regression will be based on the
random effects model to allow for residual unexplained
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significance. When the sizes of the included studies are
moderate or large, there should be at least 10 studies
for a continuous study-level variable. For a categorical
subgroup variable, each subgroup should have a minimum
of four studies. These numbers serve as the lower bounds
for considering meta-regression [49]. When included stu-
dies are mostly small in size, univariable meta-regression
will be used when an insufficient number of studies are
available to conduct multivariable analyses.
Regarding caloric intake, if highly correlated with SSB
consumption, it will be difficult to decipher the inde-
pendent effect of SSB consumption. If caloric intake lies
in the causal pathway, then adjusting for it would elim-
inate any true associations between SSB consumption
and outcomes. However, a counter-argument could be
made that failure to adjust for caloric intake would pro-
duce spurious positive associations. Due to this uncer-
tainty, we reasoned that assessing effect estimates for
this variable in a subgroup analysis was the most appro-
priate; studies will not be penalized for adjusting or not
adjusting in assessments of confounding bias.
Sensitivity analysis
Sensitivity analyses may be used to restrict analyses to
low risk of bias and any decisions made regarding data
handling.
Assessing for small study effects
We will investigate small study effects by the perfor-
mance of cumulative meta-analysis (studies ordered and
synthesized from the most to the least precise) and/or
other graphical or statistical techniques if the following
criteria are met: there are at least 10 studies available,
studies are of unequal sizes, there are no substantial cli-
nical and methodological differences between smaller
and larger studies, and quantitative results are accom-
panied with measures of dispersion [57-60].
Discussion
Grading the quality of evidence and interpretation
We will use the GRADE approach to evaluate the qual-
ity of evidence for outcomes [42]. Quality of evidence is
the level of confidence for a causal inference that authors
place in the estimate of effect for an outcome (i.e. their
judgement that the evidence reflects the true effect). As
stated previously, if surrogate measures are analysed in
lieu of decision-making endpoints, these will be graded.
When grading the evidence, reviewers will evaluate the
domains of study limitations (risk of bias), inconsistency,
indirectness, imprecision, and publication bias and down-
grade where important limitations exist. Studies may also
be upgraded based on a strong magnitude of effect that
is not due to known biases, dose-response gradient, andresidual confounding that would have reduced the ob-
served effect. The overall quality of evidence grade will be
designated as high (confident the true effect lies close to
that of the estimate), moderate (moderately confident in
the effect estimate but may be substantially different), low
(confidence in the effect estimate is limited), or very low
(very little confidence in the effect estimate) [42]. The re-
sults will be discussed in light of the strength of findings as
well as their implications for research and public health.
Quality assurance
We used the PRISMA for Protocols (PRISMA-P) check-
list for reporting this protocol [61]. This review will be
reported according to the PRISMA statement [37] and
using a Measurement Tool to Assess the Methodological
Quality of Systematic Reviews (AMSTAR) tool for ad-
ditional quality control [62]. This protocol does not up-
date any previously conducted systematic review. Any
amendments made to this protocol when conducting the
review will be outlined in the review’s manuscript.
Additional files
Additional file 1: Postulated physiologic mechanisms regarding
disease development due to SSB consumption [63-69]. This file
provides a description of the postulated physiologic mechanisms of
disease development from the consumption of sugar-sweetened
beverages.
Additional file 2: Examples of validated generic quality of life
instruments. This file provides examples of validated generic quality of
life instruments.
Additional file 3: Search strategy for the Embase, MEDLINE, and
PsycINFO databases. This file provides the search strategies used for the
various bibliographic databases.
Additional file 4: Risk of Bias Assessment. This file provides the tools
and domains for risk of bias assessment.
Additional file 5: Causal directed acyclic graphs (DAG) depicting
the postulated causal and biasing pathways between sugar-
sweetened beverage consumption and adverse health outcomes
[70-72]. This file provides illustrations and accompanying text of the
postulated causal and biasing pathways between sugar-sweetened
beverage consumption and adverse health outcomes.
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